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Neutrophil: A New Player in
Metastatic Cancers
Mengyue Wu 1†, Mutian Ma 1†, Zhenya Tan 1, Hong Zheng 1* and Xia Liu 2*
1Department of Pathophysiology, Anhui Medical University, Hefei, China, 2Department of Toxicology and Cancer Biology,
Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, United States
The interaction between cancer cells and immune cells is important for the cancer
development. However, much attention has been given to T cells and macrophages.
Being the most abundant leukocytes in the blood, the functions of neutrophils in
cancer have been underdetermined. They have long been considered an “audience”
in the development of cancer. However, emerging evidence indicate that neutrophils
are a heterogeneous population with plasticity, and subpopulation of neutrophils (such
as low density neutrophils, polymorphonuclear-myeloid-derived suppressor cells) are
actively involved in cancer growth and metastasis. Here, we review the current
understanding of the role of neutrophils in cancer development, with a specific focus
on their pro-metastatic functions. We also discuss the potential and challenges of
neutrophils as therapeutic targets. A better understanding the role of neutrophils in
cancer will discover new mechanisms of metastasis and develop new immunotherapies
by targeting neutrophils.
Keywords: metastasis, neutrophils, tumor microenvironments, circulating tumor cells, pre-metastatic niche,
immunosuppression
INTRODUCTION
Cancer is a leading cause of death worldwide, and metastasis accounts for the majority of
cancer-related mortality. However, the process of metastasis is still poorly understood yet, which
has hampered the development of effective anti-metastatic therapies. It is well-known that
metastasis is a multiple step process, which includes local tumor cell invasion, entry into the
vasculature (intravasation), survival in the circulation followed by the exit from the circulation
(extravasation) and colonization at the distal sites. At each step, cancer cells must escape from
immune surveillance and killing. Among these immune cells, focus is often given to T cells and
macrophages, whereas the functions of neutrophils in cancer have been largely overlooked until
recently and still remain elusive (1).
Neutrophils are the most abundant leukocytes in the blood. They have long been
considered play an “audience” role in the development of cancer. However, studies of the
past decade have found that neutrophils are a heterogenous population including low density
neutrophils (LDNs), normal density neutrophils (NDNs), high density neutrophils (HDN),
polymorphonuclear-myeloid-derived suppressor cells (PMN-MDSCs) and tumor-associated
neutrophils (TANs) (2). Subpopulation of neutrophils plays an important role in cancer
progression, particularly in metastasis (3–5). This review summarizes the latest advances in
understanding the role of neutrophils in cancer, with a specific focus on their pro-metastatic role.
A better understanding the pro-metastatic role of neutrophils will discover new mechanisms of
metastasis and open new avenues for immunotherapies by targeting neutrophils.
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NEUTROPHIL GRANULES,
HETEROGENEITY, AND PLASTICITY
It is well-known that neutrophils play an important physiological
role in the body. When the body is inflamed or stressed,
neutrophils are always the first to participate in the response,
and its unique function is highly dependent on the granules
secreted by the cytoplasm. During the maturation of neutrophils,
the granules continue to accumulate in the cells, and finally are
released when the neutrophils are activated, especially when they
participate in the inflammatory response. Neutrophils contain
releasable membrane-bound organelles (secretory vesicles),
which secrete three main types of cytoplasmic granules: primary
granules (azurophilic granules), secondary granules (specific
granules) and tertiary granules (gelatinase granules) (6). These
granules can be released by exocytosis or mobilized to the surface
of neutrophils by envelope fusion (7). Primary granules are the
storage ofmyeloperoxidase (MPO) andmost proteolytic enzymes
and bactericidal proteins, and are considered as bactericidal
chambers mobilized during phagocytosis. Secondary granules
are the most numerous granule and contain complement
activators and enzymes, e.g., collagenases. Tertiary granules
are particularly important in maintaining the homeostasis
of the body. They contain biological molecules involved in
the physiological processes of neutrophil superoxide anion
production, cell adhesion, and diapedesis/extravasation in the
early stage of inflammatory reaction, and are rich in matrix
metalloproteinase-9 (MMP-9). MMP-9 is considered to be an
important participant in the development of cancer (8). It not
only plays a critical role in the enzymatic reabsorption and
degradation of extracellular matrix (ECM), but also is involved
in many other aspects of tumor biology, including angiogenesis,
proliferation, invasion and movement, niche formation of cancer
stem cells, and promotion of metastatic growth (9, 10). In
addition to MMP9, neutrophils also secrete Cathepsin G and
Protease 3, and both of them participate in the inflammatory
response regulated by neutrophils (11). Cathepsin G and Protease
3 can interact with the receptor for advanced glycation end
products (RAGE) but play different roles. The interaction of
neutrophil Cathepsin G with tumor cell RAGE is required for
neutrophil cytotoxicity to kill tumor cell (12), while neutrophil
proteinase 3 interacts with tumor cell RAGE to promote the bone
metastasis of prostate cancer (13).
Peripheral blood neutrophils are a heterogeneous population
(14, 15), which is evaluated by several parameters including
functions (movement, phagocytosis, and oxidative metabolism),
physical properties (density, membrane potential), cell surface
proteins and enzyme contents. When neutrophils are stimulated
and mobilized, neutrophils may express different proteins on
the surface of cells, and then change the cell function (16). The
physical properties (density, mass, etc.) of neutrophils may also
change accordingly (17). After density gradient centrifugation,
neutrophils in peripheral blood were clustered. HDNs and
NDNs are usually deposited on top of erythrocytes. Peripheral
blood mononuclear cells (PBMCs), platelets, immature and
activated polymorphonuclear neutrophils (PMNs), LDNs, and
PMN-MDSCs are located at the interface between plasma
and Ficoll-paque layer. The reported neutrophil subpopulation
which promote the pathological process of tumors (occurrence,
invasion, and metastasis, etc.) mainly refer to LDNs including
mature subtype of LDNs and low density immature PMN-
MDSCs (18, 19).
Neutrophils can display either anti-tumor or pro-tumor
activity due to heterogeneity and plasticity. Anti-tumor and pro-
tumor neutrophils were named as N1 and N2 by Fridlender et al.
(20) in 2009. N1 anti-tumor activity is regulated by multiple
mechanisms. For example, neutrophils-mediated cancer cell
killing is dependent on hepatocyte growth factor (HGF)/MET-
induced nitric oxide release (21). N1 neutrophils also can inhibit
metastatic seeding in the lungs by generating hydrogen peroxide
(H2O2) which is mediated by tumor secreted chemokine ligand
2(CCL2) (22). Other mechanisms involved in anti-tumor activity
of neutrophils include inducing apoptosis of tumor cells by
direct contact or release of the tumor necrosis factor-related
apoptosis inducing ligand (TRAIL), antibody-dependent cell-
mediated cytotoxicity (ADCC), and activation of T cell function
(23). On the contrary, N2 neutrophils promote tumor growth
and metastasis, which will be discussed in details in the
following sections.
Like macrophages (24), N1 and N2 neutrophils can be
shifted to each other, depending on specific tumor-derived
factors. Transforming growth factor-β (TGF-β) is the well-
studied molecule that polarizes neutrophils to N2 phenotype
(20). Both TGF-β blockade and neutrophil depletion can induce
N1 phenotype and significantly decrease tumor growth in
mouse models. Recently, Interleukin (IL) 35 (IL-35) (25) has
also been found to promote the neutrophil polarization to N2
phenotype, IL-35 promotes the production of granulocyte-colony
stimulating factor (G-CSF) and IL-6, activates signal transducer
and activator of transcription 3 (STAT3) and extracellular signal-
regulated kinase (ERK) pathways in neutrophils, and increases
the expression of inducible nitric oxide synthase (iNOS) to
inhibit T cell activity. In addition, studies have shown that
type I interferon (IFN) can transform neutrophils into N1
anti-tumor phenotype (26, 27). In the absence of IFN-β, the
expression of neutrophil extracellular trap (NET) in primary
lesions and pre-migratory lung is low, while the use of interferon
therapy in mouse tumor models polarizes neutrophils to N1
anti-tumor phenotype (27). Cytokine concentration and tumor
microenvironment (such as hypoxia) changes may also be
important for neutrophil polarization. It has been reported
that neutrophils display an activated phenotype with anti-
tumor role to stimulate T cell responses in the early stage of
tumors (28), but with the development of tumors, it gradually
becomes N2 phenotype. In addition, N1 neutrophils have a
shorter life span, but are more mature and cytotoxic than N2.
Therefore, conversion from N2 to N1 phenotypes of neutrophils
might be a new way to reactivate anti-tumor immune response
of neutrophils.
NEUTROPHILS: THE LINKING BETWEEN
INFLAMMATION AND CANCER
Neutrophils are the first responders to sites of infection and
tissue damage. Healthy people can produce more than 1011
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neutrophils per day in the bone marrow (29). Neutrophils are
thought to be a short-lived cell type. However, their lifespan
is much longer than initially thought and can survive for
more than 5 days in the circulation, and may potentially live
even for weeks in tissues (30). They are highly mobile and
rapidly recruited to infected or injured tissues by multiple
signals including cytokines, chemokines, and pathogen signals.
Even after the death of neutrophils, its residual DNA structure
will form a unique network structure called NET (31, 32),
which captures and kills pathogens in the body. However,
several lines of evidence have shown that neutrophil functions
extend beyond their roles in innate immune response to kill
microorganisms, but also contribute to chronic inflammatory
conditions and adaptive immune responses, which have been
reviewed in detail elsewhere (33–35). Better understanding
how neutrophils are recruited and subsequently react to
inflammation could help to understand how inflammation
induces cancers.
The difference between neutrophils and other immune cells
is that they are released from bone marrow as ultimately
differentiated mature cells (36). In the different stages of
neutrophil differentiation, a variety of cytoplasmic granules
with different functions are continuously synthesized, which
is the basis for neutrophils to play their cellular functions.
Under normal condition, circulating mature neutrophils account
for only 1–2% of all neutrophils in the whole body. Mature
neutrophils are retained in bone marrow through interaction
between two C–X–C chemokine receptors (CXCR): CXCR4 and
CXCR2 (37–39). CXC chemokine ligand (CXCL) 12, which
is produced by osteoblasts and other bone marrow stromal
cells, binds CXCR4+ neutrophils to maintain them in the
bone marrow. While the secretion of CXCL1 and CXCL2 by
endothelial cells and megakaryocytes encourages neutrophils to
release into circulation via CXCR2 signal (40). Other adhesion
molecules such as integrin subunit alpha 4 (ITGα4), vascular
cell adhesion molecule 1 (VCAM-1), and some proteases play an
important role in neutrophil retention (41, 42). In addition, IL-23
produced by macrophages and IL-17 produced by lymphocytes,
can also regulate the release of neutrophils (43).
The presence of white blood cells within tumors was
first observed in the 19th century by Rudolf Virchow. It is
now recognized that inflammation plays an important role in
the occurrence and development of cancer (44–46). Among
white blood cells, neutrophils are the common inflammatory
cell type infiltrated in many tumors. Albrengues et al. (47)
found that persistent experimental pulmonary inflammation
induced by exposure to tobacco smoke or nasal instillation
of lipopolysaccharide (LPS) and the accompanying formation
of NET can wake up dormant cancer cells to transform
them into invasive lung metastasis in mice. Awakening of
these dormant cancer cells is associated with NET-mediated
remodeling of the extracellular matrix. Antonio et al. (48)
also found that injury-induced inflammation increases the
formation of tumors in a neutrophil-dependent manner in a
HrasG12V-driven melanoma zebrafish model. A recent study
further suggested that microparticles (such as miR-23a miR-155)
released by neutrophils in inflamed tissue can induce genomic
instability to promote cancer development (49). Therefore
better understanding the correlation between pro-inflammatory
function of neutrophils and cancer development could foster a
new anti-inflammatory therapeutic approach to treat cancer.
EARLY METASTATIC STEP-NEUTROPHILS
AT TME
Tumormicroenviroment (TME) is the environment surrounding
a tumor, which plays an important role for the tumor initiation,
growth, and metastasis (50, 51). Multiple immune cell types,
including lymphocytes (T cells and B cells) (52, 53), neutrophils
(54), macrophages (55), dendritic cells (DCs) (56), and nature
killer (NK) cells (57) have been shown to infiltrate the TME.
Despite being the major component of the immune system, the
contribution of neutrophils to the tumors has been overshadowed
by other immune cells such as lymphocytes and macrophages.
However, increasing evidence shows that neutrophils also
actively participate in regulating TME and tumor progression,
which is related to N2 phenotype of neutrophils. This section is
focused to discuss the pro-tumor/metastatic role of neutrophils
in TME.
Angiogenesis is the physiological process through which the
new blood vessels form. However, it is also a fundamental
step in the transition of tumors from benign to malignant
state. The role of neutrophils in tumor angiogenesis has been
previously reviewed (58, 59), and the mechanisms include
releasing a variety of proteases (such asMMP9), directly secreting
a multitude of soluble pro-angiogenic factors [such as vascular
endothelial growth factor (VEGF)], and through intimate cell-
to-cell interactions with endothelial cells. In addition, Bv8 is
an important mediator of neutrophil-dependent angiogenesis,
and blocking Bv8 function can inhibit angiogenesis and tumor
growth (60, 61). Recently, transcriptomic analyses demonstrated
that pro-angiogenic genes including vegfa, itgb1, il1b, mmp14,
and mmp9 as well as genes encoding other cell adhesion
molecules, such as ilgals1 and igals3bp, are upregulated in TANs
(62), further confirming a prominent role of neutrophils in
promoting tumor angiogenesis.
Recruitment of neutrophils to the TME is regulated by
various cytokines, chemokines and signals. Interleukin 17 (IL-
17) is a pro-inflammatory cytokine. Both clinical sample and
experimental studies have shown that IL-17 produced by T
helper 17 cells can recruit CD15+ neutrophils into TME of
hepatocellular carcinoma (HCC) by epithelium-derived CXC
chemokines (63) (Figure 1). Subsequently, neutrophils stimulate
the proangiogenic activity of tumor cells at adjacent invading
edges by producing MMP9. Mesenchymal stromal cells (MSCs)
can also infiltrate into TME to recruit neutrophils (64). Yu
et al. (65) found that Tumor necrosis factor-α (TNF-α)-activated
MSCs promote breast cancer metastasis via production of
CXCL1, CXCL2, and CXCL5 to recruit CD11b+Ly6G+ CXCR2+
neutrophils, and then neutrophils activate tumor cells to express
higher levels of metastasis-related genes including CXCR4,
CXCR7, MMP12, MMP13, IL-6, and TGFβ . In HCC, high
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FIGURE 1 | The role of neutrophils in TME. (A) γδ17T cells which secret IL-17 can recruit neutrophils into TME to stimulate the angiogenesis by producing VEGF and
MMP9. In addition, γδ17T cells can produce G-CSF to expand, and polarize neutrophils to promote metastasis by suppressing cytotoxic CD8T cells immunity.
(B) eIF4E is phosphorylated by MNK1/2 to promote neutrophils survival and accumulation in TME due to increased expression of BCL2 and MCL1, which then
promote metastasis. (C) Estradiol (E2) promotes N2 polarization of neutrophils via TGF-β1, thus causing cancer cells to be highly metastatic. (D) TNFα-activated
MSCs promote metastasis via production of CXCL1, CXCL2, and CXCL5 to recruit CXCR2+ neutrophils, and then neutrophils activate tumor cells to express higher
levels of metastasis-related genes including CXCR4, CXCR7, MMP12, MMP13, IL-6 and TGFβ. In addition, tumor cells secreted GM-CSF can induce neutrophils to
produce HGF, which binds to c-Met on tumor cells to promote metastasis. (E) Tumor-derived GM-CSF induces PD-L1 expression on neutrophil via
JAK-STAT3signaling pathway, and cancer-associated fibroblasts (CAFs) induce PD-L1 expression on neutrophils by IL6—STAT3 signaling pathway, both of which
inhibit T-cell immunity. In addition, c-Kit+ neutrophils use fatty acid oxidative metabolism to support ROS production to mediate T cell suppression.
infiltration of neutrophils in tumor tissues correlates with c-
Met-associated worse patient outcomes (66). The infiltrated
CD66b+ neutrophils are the major source of c-Met ligand
hepatocyte growth factor (HGF) in HCCs. Exposure to HCC
environments activates neutrophils and the following HGF
production, which then enhance the metastasis of malignant
cells by HGF/c-met interaction. HCC cell-derived granulocyte-
macrophage colony stimulating factor (GM-CSF) is an important
determinant in neutrophil HGF production, which in turn
enhances the migration and invasion of HCC cells (66). However,
c-Met expression on neutrophils induced by tumor-derived
TNF-α or other inflammatory stimuli is required for neutrophil
chemoattraction and cytotoxicity in response to HGF (21).
Consequently, c-Met deletion in neutrophils enhances tumor
growth and metastasis. Neutrophils recruited to the TME also
actively secrete cytokines and chemokines, which not only
enhance their own recruitment but also the recruitment and
polarization of other immune cells in the TME, which will be
discussed in detail later.
Cell–cell interactions in TME can be enhanced by integrins,
which plays a critical role in cancer cell growth and metastasis
(67–69). A recent study demonstrated that Estradiol (E2)
promotes breast cancer metastasis by enhancing cell–cell
interactions between neutrophils and ER+ breast cancer cells
in TME (70). E2 treatment promoted N2 polarization of
neutrophils by inducing expression of the lymphocyte function-
associated antigen 1 (LFA-1, CD11a/CD18) integrin via elevated
transforming growth factor β1 (TGF-β1), leading to cancer
cell migration from the primary tumor site to distant organs.
Interestingly, these interactions also caused non-metastatic cells
to become highly metastatic.
The effect of translation changes on gene expression is
much faster than transcriptional alterations (71). Deregulated
translation is a hallmark of transformation, uncontrolled cell
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FIGURE 2 | Neutrophils interact with CTCs to promote metastasis. CTC-associated neutrophils express VCAM-1 to mediate their interaction, and produce IL-1β and
IL-6 to support CTC proliferation, leading to enhanced metastatic potential of CTC clusters. Both CTC clusters and neutrophil-CTC clusters can prevent CTCs from
being killed by NK cells and T cells. In addition, β1-integrin mediated interactions between CTCs and NETs can trap CTCs, thereby promoting adhesion of CTCs to
distant organs and metastasis.
proliferation, and survival, as well as the metastatic ability of
cancer cells. The best-studied translational regulator involved
in cancer is the eukaryotic translation initiation factor 4E
(eIF4E), which is regulated via phosphorylation of serine 209
by the mitogen-activated protein kinase integrating kinases
1/2 (MNK1/2) (72). A recent study showed that translational
control by eIF4E in the TME plays a crucial role in metastatic
progression. Further investigation indicated that phospho-eIF4E
promotes neutrophil survival and accumulation in TME due
to increased expression of the anti-apoptotic proteins 2 B-cell
lymphoma (BCL2) and myeloid cell leukemia 1(MCL1) (73).
CIRCULATING NEUTROPHILS, NETS, AND
CIRCULATING TUMOR CELLS
Circulating Tumor Cells (CTCs), are tumor cells that have shed
into the blood circulation from a primary tumor or metastatic
lesions. They are considered “seeds of metastasis.” It is known
that CTCs exist as either single cells or CTC clusters which are
defined as a group of more than two or three tumor cells. While
rare, several recent studies have shown that CTC clusters with
enhanced stem cell properties have increased capacity to seed
metastases (74–77).
Interaction between cancer cells and immune cells is
important for the cancer development. However, focus is often
given to those interactions that occur within the primary tumor
and its microenvironment, and pre-metastatic niche, while the
role of immune cells during cancer dissemination in circulation
remains largely unknown. CTCs are occasionally found in
association with non-malignant cells such as leukocytes (78,
79). By single-cell RNA sequencing of cluster-associated white
blood cell (WBC), Szczerba et al. (80) found that the vast
majority (85.5–91.7%) of CTC-associated WBCs are CD11b+Ly-
6G+ neutrophils. The association between neutrophils and
CTCs drives cell cycle progression to confer proliferative
advantage of CTC clusters (80), leading to faster metastasis
development and enhanced metastatic potential of CTC clusters.
Further RNA sequencing analysis revealed ARG1, CXCL1,
CXCL2, CXCL10, CCL2, CXCR2, and VEGFA are expressed
in most CTC-associated neutrophils, indicating that CTC-
associated neutrophils are similar to N2 phenotype (Figure 2).
CTC-associated neutrophils express VCAM-1 to mediate their
interaction with CTCs, and TNF-α, oncostatin M (OSM),
IL-1β, and IL-6 to support CTC proliferative advantage. In
addition, intercellular adhesion molecule-1 (ICAM-1) was also
found to mediate CTCs and neutrophil interaction to promote
liver metastasis (81). Based on these two studies, VCAM-
1 and ICAM-1 might play the roles at different stages.
VCAM-1 mediates interactions between neutrophils and CTCs
in the circulation, while ICAM-1 mediates interaction between
arrested neutrophils and CTCs to facilitate tumor cells adhesion
to the endothelium. Therefore, the link between VCAM-1
and ICAM-1 in metastasis remains to be elucidated in the
future studies.
NETs are neutrophil-derived DNA networks released in
response to inflammatory signals that trap and kill invading
pathogens (82). Several evidences have shown that NETs
are involved in trapping CTCs and promote metastasis (83,
84). In 2013, Cools-Lartigue et al. (84) provided the first
evidence suggesting that NETs are able to trap CTCs, thereby
promoting early adhesion of CTCs to distant organ sites and
metastasis. These effects are abrogated by NET inhibition with
deoxyribonuclease (DNase) or elastase inhibitor. Later in 2017,
Najmeh et al. (83) shed light on the molecular mechanism
by which NETs trap CTCs. They found that β1-integrin is an
important factor mediating the interactions between CTCs and
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NETs. Both studies have shown that interactions between CTCs
and NETs can be abrogated by DNase, suggesting the potential of
NETs as potential therapeutic targets.
CTCs face many survival challenges in the circulation,
including immune cell attack, and shear forces. Understanding
how CTCs survive will facilitate to develop efficient anti-
metastatic treatment. Comparing to single CTCs, CTC clusters
have increased expression of NK cell inhibitory ligand HLA
and decreased expression of NK cell activating ligand NKG2D,
leading to reduced NK cell activation and killing (85). In
addition, Zhang et al. (86) found that circulating neutrophils can
contribute to CTC survival by suppressing peripheral leukocyte
activation to enhance metastasis. Recently, Dr. Millinedo
hypothesized (87) that CTCs might interact with neutrophils as a
strategy to evade immune detection and attack, which is similar
as Leishmania parasites do (88). In this proposed hypothetical
model, cancer cells could be transported and protected from
immune cell attacks by being surrounded by neutrophils.
However, this hypothesis remains to be further investigated.
NEUTROPHILS IN TUMOR CELLS
EXTRAVASATION
While CTCs use various strategies to survive in the intravascular
environment, their metastatic potential eventually depends on
their ability to rapidly extravasate (exit the vessel) into the
surrounding tissue. It is well-accepted that extravasation involves
arrest in small capillaries and adhesion to the endothelium,
rearrangements of the endothelial barrier, and transendothelial
migration to the underlying tissues (89). Although extravasation
is crucial for metastases, mechanisms underlying this complex
process remain to be fully understood.
Neutrophils participate in the inflammatory response
by transendothelial migration, which include three steps:
neutrophils rolling, adhesion, and migration (90, 91).
Neutrophils rolling is mediated by L-selectin expressed
on neutrophils and E-selectin and P-selectin expressed on
endothelial cells (Figure 3). More importantly, both neutrophils
adhesion and migration require the expression of CD11a/CD18
(LFA-1) and CD11b/CD18 (Mac-1) on neutrophils and the
expression of ICAM-1 on endothelial cells (92).
Accumulating evidence suggest that neutrophils canmodulate
tumor cell attachment to endothelial cells, which is mediated
by a mechanism involving direct contact between neutrophils,
tumor cells, and the endothelial cell monolayer. Using an in vivo
model of early metastasis coupled with intravital microscopy,
McDonald et al. (93) provided evidence that neutrophils promote
metastasis by facilitating CTCs adhesion to liver sinusoidal
endothelium, which is dependent on selectin ligands containing
Sialyl-Lewis X (sLeX) moieties on the surface of the tumor
cells and E-selectin on endothelial cell expression. Consistently,
Spicer et al. (81) also found that neutrophils promote cancer
cell adhesion within liver sinusoids to promote liver metastasis
viaMac-1-mediated interactions with ICAM-1-expressing CTCs.
Under flow conditions, transmigration of C8161 melanoma
cells can be influenced by neutrophils, which is mediated by
Mac-1/ICAM-1 adhesive interactions and enhanced by altered
IL-8 cytokine production (94). Melanoma cell-secreted IL-8
attracts neutrophils and increases tethering Mac-1 expression
on neutrophils to promote anchoring to vascular endothelium
(95). However, Mac-1 only affects prolonged neutrophil-
melanoma aggregation. While LFA-1 influences the capture
phase of neutrophils binding to both melanoma cells and the
endothelium (96).
Tumor cells can alter neutrophils function to facilitate their
extravasation. For example, tumor-conditioned medium (TCM)
downregulates neutrophils cytocidal function, delays neutrophils
apoptosis, and upregulates adhesion molecule expression on
neutrophils. These neutrophils treated with TCM can attach
to tumor cells and facilitate their migration through different
endothelial monolayers (97).
To dissect the dynamic roles of inflamed neutrophils
during hematogenous dissemination, a multiplexed microfluidic
model of the human microvasculature was developed to
observe heterotypic tumor cell–neutrophils interactions (98).
Surprisingly, neutrophils are not static following aggregation,
but exhibit a dynamic migration pattern near tumor cells–
neutrophils clusters. The initial clustering of tumor cells and
neutrophils is dependent on both physical trapping and adhesive
interactions between neutrophils and endothelial ICAM-1. After
arrest, neutrophils within clusters are highly migratory, in a
confined manner mediated by neutrophils self-secreted IL-8
and tumor-derived CXCL-1. This induces significant neutrophil
sequestration with arrested tumor cells, leading to the spatial
localization of neutrophil-derived IL-8, and increasing the
extravasation potential of nearby entrapped tumor cells through
disruption of the endothelial barrier. These findings provide a
basis for inhibiting the pro-extravasation effect of neutrophils to
reduce metastasis.
In addition, neutrophils can enhance metastasis formation
via another two distinct mechanisms. First, CD11b+Ly6G+
neutrophils increase the intraluminal survival time of tumor cells
by inhibiting natural killer (NK) cell function (99). Secondly,
CD11b+ Ly6G+ neutrophils expedite extravasation of tumor
cells through the secretion of IL1β and MMPs (99). IL1β is a
cytokine that is known to be secreted by neutrophils, to activate
endothelial cells, and to increase leukocyte extravasation (100).
Therefore, these results suggest that neutrophils facilitate tumor
transendothelial migration not only through a direct effect on the
tumor cells but also through their activation of endothelial cells.
NEUTROPHILS IN PRE-METASTATIC
NICHE
After successful extravasation, tumor cells have to survive
and outgrow under a novel pre-established and favorable
environment in distant organ to form metastasis. This
microenvironment is termed pre-metastatic niche by
Dr. David Lyden’s lab in 2005 (101). Several studies have
shown that neutrophils play an important role in this niche to
promote metastasis.
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FIGURE 3 | Neutrophils facilitate CTCs extravasation. E/P-selectin on the endothelial cell mediates the initial attachment and rolling of neutrophils along the
endothelial surface. Then neutrophils capture tumor cells via LFA-1 and ICAM-1 interactions. LFA-1 on neutrophils also bind to ICAM-1 on the endothelial cells to
arrest and activate neutrophils. After arrest, neutrophils within clusters are highly migratory mediated by neutrophils self-secreted IL-8 and tumor-derived CXCL-1. On
the other hand, tumor cell secreted IL-8 increases Mac-1 expression on neutrophils to promote their binding to ICAM-1 on endothelial cells, and also prolong
interaction with CTCs via Mac-1-mediated interactions with ICAM-1-expressing CTCs. Neutrophils can also facilitate CTCs adhesion to endothelium, which is
dependent on selectin ligands containing sialyl-Lewis x (sLex) moieties on the surface of the tumor cells and E-selectin on endothelial cells. Together, neutrophils
increase the extravasation potential of nearby entrapped tumor cells through disruption of the endothelial barrier.
FIGURE 4 | The role of neutrophils in pre-metastatic niche. Primary tumor cells secret various cytokines, chemokines, and signals to recruit neutrophils to distant
organs to form pre-metastatic niche. For example, tumor cell secreted-IL-8, MCP-1, GROα, GROβ, and G-CSF can mobilize neutrophils to the pre-metastatic niche,
which then facilitate colonization of tumor cells and subsequent metastasis; GM-CSF produced by tumor cells can induce transferrin synthesis in neutrophils through
the Jak/Stat5β pathway; TIMP-1 increases SDF1 levels, which in turn promote recruitment of neutrophils to the liver to promote liver metastasis; tumor exosomal
RNAs activate TLR3 to induce chemokines that are critical for neutrophil recruitment and lung pre-metastatic niche formation. At pre-metastatic niche, activated
neutrophils produce IL-1β, TNF-α, IL-6, and Cox-2, and degranulate azurophilic granules to release elastase and cathepsin G, leading to degradation of the Tsp-1 and
enhanced metastasis. In addition, neutrophils support metastatic lung colonization via ALOX5-dependent leukotriene (LT) synthesis/release.
Accumulation of neutrophils in the pre-metastatic niche is
regulated by various cytokines and chemokines. In colorectal
cancer, tissue inhibitor of metalloproteinases-1 (TIMP-1)
promotes liver metastasis by triggering the formation of a
pre-metastatic niche (Figure 4). This effect is dependent on
the increased hepatic stromal cell-derived factor 1 (SDF-1)
levels, which in turn promote CXCR4-dependent recruitment of
neutrophils to the liver (102). CXCR2-dependent accumulation
of Ly6G+ neutrophils in the pre-metastatic niche is required
for pancreatic ductal adenocarcinoma (PDAC) metastasizing
to liver (103). In addition, tumor cell secreted G-CSF can
mobilize Ly6G+Ly6C+ granulocytes to the pre-metastatic
niche, which then facilitates colonization of tumor cells and
subsequent metastasis (3). The absence of type I IFN can
also induce CD11b+Ly6G+Ly6Cint neutrophil-mediated
pre-metastatic niche formation due to upregulated CXCR2
expression (104). This finding further support that type I IFN
transform neutrophils into N1 anti-tumor phenotype (27).
Neutrophil accumulation in lungs supports more efficient
tumor cell extravasation and proliferation in the lung due to the
enhanced expression of pro-metastatic proteins, such as Bv8,
MMP9, S100A8, and S100A9 (104).
Exosomes are a class of extracellular vesicles released by all
cells, with a size range of 30–200 nm (105). They play a key role
in intercellular communication between cancer cells and their
microenvironment through transfer of information via their
cargo including proteins, DNAs, RNAs, and microRNAs (106–
108). Emerging evidence suggests that tumor-derived exosomes
can induce the formation of pre-metastatic niche that foster
the development of metastatic disease (109, 110). Interestingly,
tumor exosomal RNAs activate alveolar epithelial toll-like
receptor 3 (TLR3) to induce chemokines (CXCL1, CXCL2,
CXCL5, and CXCL12) that are critical for neutrophil recruitment
and lung pre-metastatic niche formation (111). Tumor-derived
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exosomes can also induce N2 polarization of neutrophils to
promote gastric cancer cell migration (112) and NETs to establish
cancer-associated thrombosis (113).
Inflammation is strongly associated with primary tumor
progression, however, little is known about its role in metastatic
outgrowth in distant organs. Thrombospondin-1 (Tsp-1) is
a secreted ECM protein critical for lung homeostasis and
inflammation (114). It has been shown that myeloid cell-
derived Tsp-1 contributes to inhibition of metastasis (115). A
study from EI Rayes et al. (114) provided mechanistic insights
into the contribution of inflammatory neutrophils to metastasis
by degradation of Tsp-1. In the study, they demonstrated
that inflammation in the lungs leads to the recruitment of
bone marrow-derived CD45+CD11b+Ly6G+ neutrophils. These
activated neutrophils produce potent inflammatory mediators,
including IL-1β, TNF-α, IL-6, and cyclooxygenase-2 (Cox–2),
and degranulate azurophilic granules to release elastase and
cathepsin G, leading to degradation of the Tsp-1 and enhanced
metastasis. Importantly, genetic ablation of these neutrophil
proteases can inhibit lung metastasis.
Neutrophils are the major component and driver of metastasis
formation within the pre-metastatic niche inmouse breast cancer
models (4, 116). Neutrophils infiltrate the metastatic sites before
the tumor cells and promote metastasis without effect on the
growth of primary tumors. Conditioned medium from pre-
metastatic lung neutrophils contains high level of leukotrienes
(LTs), the products of the arachidonate 5-lipoxygenase (ALOX5)
enzyme, which promote tumor sphere growth in vitro and
increase the metastatic initiation potential of cancer cells in
vivo (4). Importantly, ALOX5 inhibitor zileuton can inhibit
LT production in vivo and reduce spontaneous metastasis,
suggesting that targeting LT/ALOX5 is a potential therapeutic
strategy to reduce metastasis. However, deletion of ALOX5
in TME promotes lung cancer progression and metastasis by
decreasing T cell number (117). These findings suggest that
caution should be taken in targeting ALOX5 in lung cancer due
to anti-tumorigenic role of ALOX5 in TME through regulation
of T cells.
Tumor cells are preferentially colonize and metastasize to
specific organs, which is called “organotropic metastasis” (118).
A recent study provided the evidence showing that neutrophils
are involved in ovarian cancer organotropic metastasis to
the omentum by establishing pre-metastatic niche (119).
Ovarian tumor–derived inflammatory factors, including IL-8,
monocyte chemoattractant protein-1 (MCP-1), growth-regulated
oncogene–α and–β (GROα and GROβ), and G-CSF, stimulate
neutrophils to mobilize and NET formation in the omentum.
NETs, in turn, trap ovarian cancer cells and promote metastasis.
Inhibition of NET formation decrease omental colonization,
raising the possibility that blockade of NET formation prevents
omental metastasis.
The colonized metastatic cells can also promote pro-
metastatic function of neutrophils. By analyzing the
secretome of neutrophils isolated from tumor-bearing
mice, the iron-transporting protein transferrin secreted by
Ly6G+ neutrophils was identified as the major mitogen
for tumor cells (120). GM-CSF produced primarily by
tumor cells induces transferrin synthesis in neutrophils
through the Janus kinase (Jak)-Stat5β pathway. Depletion of
neutrophils, GM-CSF neutralization or inhibition of Jak kinases




Immunosuppression is a unique signature of tumor. Several
lines of evidence suggest that neutrophils can suppress
both innate and adaptive immune response during cancer
development and metastasis (121, 122). Tumor cells can
reprogram of myeloid differentiation in bone marrow to
activate neutrophils. For example, G-CSF can reconstruct the
hematopoietic function of bone marrow and promote myeloid
differentiation, thus increasing the number of neutrophils with
immunosuppressive effect in breast cancer (123). Interestingly,
activation of neutrophils in bone marrow of tumor-bearing
mice shows two different phases (124). In the mice with
early-stage tumor, CD11b+Ly6CloLy6G+ neutrophils are lacking
of immunosuppressive activity, but have elevated rates of
glucose metabolism, increased adenosine triphosphate (ATP)
production, and enhanced spontaneous migration. However, in
ectopic tumor and late stages of cancer, bone marrow neutrophils
demonstrate potent immunosuppressive activity. Since pro-
tumor LDNs accumulate continuously with cancer progression
(2), it is possible that the functional differences of neutrophils
during cancer progression correlates with the transition from
HDNs to LDNs, which warrants further investigation.
Neutrophils can also play its immunosuppressive role by
degranulation and releasing type 1 arginase (Arg I) to degrade
arginine (122). Consistently, Hawila et al. (5) found that
CCR5 regulates the immunosuppressive effect of MDSC at
tumor sites by enhancing the production of Arg I. Arginine
is important for maintain the activity of T-cell through
expression T-cell coreceptor CD3ζ, while Arg I can degrade
arginine. Therefore, T-cell suppression can be completely
restored through pharmacologic Arg I inhibition or with
arginine supplementation.
Programmed death ligand 1 (PD-L1, also known as B7-H1
or CD274) is an important co-inhibitory molecule that interacts
with programmed death 1 (PD-1) on T cells to block their
proliferation, survival and activity (125, 126). In gastric cancer
(GC), tumor-derived GM-CSF activates neutrophils and induces
PD-L1 expression on neutrophil via Jak-Stat3 signaling pathway,
therefore inhibiting T-cell immunity and contribute to the GC
progression (127). In HCC, PD-L1+ neutrophils are accumulated
in the peritumoral region of patients, and effectively suppress the
proliferation and activation of T cells (128). In addition, cancer-
associated fibroblasts (CAFs) can also induce PD-L1 expression
on neutrophils to impair T-cell function by IL6 - Stat3 signaling
pathway (129) (Figure 1).
Recent study demonstrated that mitochondrial function
is correlated with immunosuppressive capacity (130). By
characterizing neutrophil mitochondrial function, Rice et al.
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(131) found that immature, c-Kit+ neutrophils can use
mitochondrial fatty acid oxidative metabolism to maintain
intracellular nicotinamide adenine dinucleotide phosphate
(NADPH) levels and support reactive oxygen species (ROS)
production to mediate T cell suppression even in the nutrient
limited TME. These data suggest that neutrophil mitochondrial
metabolism could be an effective target for cancer therapy.
Lymphocyte-derived IL-17 regulates neutrophil expansion
via induction of G-CSF (132, 133). In breast cancer, IL-17–
producing γδ T cells (γδ17 T cells) can produce G-CSF to expand
and polarize neutrophils (132). These activated CD11b+Ly6G+
neutrophils acquire the ability to suppress cytotoxic CD8T cells,
thereby promoting metastasis (134). However, neutrophils can
also inhibit pro-tumor γδ17 T cells via induction of oxidative
stress in the TME (135). Therefore, the interactions between
neutrophils and γδ T cells in immunoregulation are complex and
warrant further investigation.
Tumor cell-released autophagosomes (TRAP) can suppress
T cell activities by inducing IL-10-producing B cells (136).
However, the mechanism of TRAP-mediated immune
suppression is still largely unknown. A recent study provided
a mechanistic insight indicating neutrophils are involved in
TRAP-mediated immune suppression (137). TRAPs can be
effectively and rapidly phagocytized into neutrophils, and
induce neutrophil apoptosis via ROS generation and caspase-3
activation. Consequently, the apoptotic neutrophils that have
phagocytized TRAPs inhibit the proliferation and activation of T
cells in a cell contact- and ROS-dependent manner (137).
Mature neutrophils can acquire a suppressor phenotype
after stimulation via complement component 3(C3) (138, 139).
Complement receptor 3 (CR3; Mac-1; CD11b/CD18) mediates
neutrophils recruitment and adhesion by binding to ICAM-
1 on endothelial and T cells. C3d plays a central role in
the complement system, and enhances antitumor immunity by
increasing tumor-infiltrating CD8+ T cells, depleting Tregs, and
suppressing PD-1 expression on T cells (140). Ascites from
patients with high-grade serous ovarian cancer (HGSOC) can
induce the suppressor phenotype in neutrophils from healthy
donors (141). However, inhibition of C3 activation abrogates the
neutrophils suppressor phenotype (139), supporting the concept
of targeting complement to enhance immunotherapy.
NEUTROPHILS AS THERAPEUTIC
TARGETS IN CANCER: CHALLENGES AND
OPPORTUNITIES
Although the potential to targeting neutrophils in cancer patients
has yet to be tested, both preclinical and clinical findings provide
a scientific rationale to therapeutic targeting pro-tumor and
pro-metastatic neutrophils. Importantly, the cancer field can
benefit from already-existing neutrophil-targeting compounds
that have been developed for the treatment of inflammatory and
autoimmune disease. For example, anti-asthma drug zileuton,
an ALOX5 inhibitor, can reduce cancer metastasis in animal
models by targeting pro-metastatic neutrophils (4). It would
be interesting to assess the correlation between asthma patients
treated with zileuton and their cancer risk.
Strategies to targeting neutrophils include the inhibition
of their migration by blocking CXCR2 (142, 143). The first
clinical trials of CXCR1 and CXCR2 inhibitor, Reparixin,
are ongoing in some cancer patients (clinical trial study
numbers: NCT02370238, NCT02001974, and NCT01861054).
IL-23-IL-17 axis is also involved in neutrophil recruitment
(144), which provide another treatment approach. Antagonists
targeting IL-23p40 (a subunit of IL-23) and IL-17 have
been approved by the US Food and Drug Administration
(FDA) for the treatment of psoriasis. Interestingly, IL-17
expression from γδ T cells induces expansion and polarization
of neutrophils to promote breast cancer metastasis (134),
suggesting γδ T cell/IL-17/neutrophil axis might represent
a new strategy to inhibit metastatic disease. As mentioned
above, activated neutrophils can induce immunosuppression,
so overcoming neutrophil-induced immunosuppression may
be one way to synergize current T cell checkpoint inhibitor
immunotherapies. Indeed, preclinical studies have shown
that combination of anti-PD-1 inhibitor with anti-CXCR2
treatment has synergistic effect to delay tumor growth (145).
This concept is also supported by the emerging clinical
evidence showing that high neutrophil counts in melanoma
patient is associated with poor response to Ipilimumab, a
fully monoclonal antibody against human anti-cytotoxic T
lymphocyte-associated antigen (CTLA)-4 (146). The inhibitory
receptor signal regulatory protein-α (SIRPα) is a myeloid-
specific immune checkpoint that engages the “don’t eat me”
signal CD47 expression. Recent study suggested that anti-human
SIRPα antibody, KWAR23, greatly enhances neutrophil and
macrophage activity (147).
Although targeting neutrophils appears to be a promising
strategy, several challenges particularly related to specificity
and safety remain (148). Since their close relationship with
other myeloid cells, unselectively targeting neutrophils may
have impacts on other immune responses. Therefore, increasing
selectivity to target neutrophils are critical for future therapeutic
development. Krupa et al. (149) reported one potential approach
by conjugating Bruton’s tyrosine kinase(Btk) siRNA to an
F(ab
′
)2 fragment of an anti-neutrophil monoclonal antibody
to selectively inhibit Btk in alveolar neutrophils, highlighting
the potential to selectively target neutrophils. In addition,
neutrophil-targeting therapeutics must be developed with
caution because neutrophils have both anti-tumor and anti-
metastatic activities in some experimental setting (20, 22). The
possible causes of these discrepancies could be due to neutrophils
heterogeneity and plasticity, and the different stages of diseases.
Therefore, another strategy is to direct N2 toward N1 neutrophil
phenotype conversion. Indeed, TGF-β blockade and TGF-β
receptor inhibitors have shown anti-tumor effects in several
models (150, 151). Since TGF-β can induce a N2 pro-tumor
neutrophil phenotype, stimulation an N1 anti-tumor phenotype
by TGF-β blockade and inhibitor could contribute to their effects
on tumors. Other challenges include reduced efficacy of other
treatment, neutropenia, and susceptibility to infection caused by
neutrophils depletion.
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CONCLUSION
Neutrophils are new players in cancer development and
metastasis. However, neutrophils also play anti-tumor/anti-
metastatic roles in some cases. The opposite effects of neutrophils
in cancers could be due to the heterogeneity and plasticity
of neutrophils. In addition, the tumor types and the stages
of diseases may also contribute the different functions of
neutrophils. Although anti-tumor/metastatic neutrophils do not
only have immunosuppressive activity, they are sometimes
overlapping with PMN-MDSCs. Because there are no available
markers can distinguish these populations. Whether they are
different subpopulation of neutrophils, or completely different
cell types is still controversial. Identification of specific markers
and better characterization of these two types of neutrophils
could help to answer these questions.
Neutrophils have a potential role as therapeutic targets
(152). New insights into the mechanisms about pro-tumor/pro-
metastatic role of neutrophils and neutrophil plasticity will
facilitate developing neutrophils-targeting agents and novel
therapeutic strategies for patients with advance disease in the
near future. However, these agents have to selectively target the
pro-tumor/pro-metastatic neutrophil subsets while preserve or
boost the anti-tumor/anti-metastatic subsets of neutrophil. Given
that neutrophils also play important role in innate immunity,
complete suppression of this cell population will put patients
at high risk to infections. A promising direction is to identify
the regulators and signaling pathways that mediate the tumor-
supporting functions of neutrophils and design therapeutics that
specifically target these regulators and pathways.
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